Malesia - inglese - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

unimed sdn bhd - cilastatin sodium; imipenem -

Canada - inglese - Health Canada

merck frosst canada & cie, merck frosst canada & co. - imipenem; cilastatin (cilastatin sodium) - powder for solution - 250mg; 250mg - imipenem 250mg; cilastatin (cilastatin sodium) 250mg - carbapenems

Malta - inglese - Medicines Authority

merck sharp & dohme limited hertford road, hoddesdon, hertfordshire en11 9bu, united kingdom - cilastatin, imipenem - powder for solution for infusion - cilastatin 500 mg imipenem 500 mg - antibacterials for systemic use

Stati Uniti - inglese - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - allopurinol sodium (unii: 428673rc2z) (allopurinol - unii:63cz7gjn5i) - allopurinol 500 mg in 25 ml - allopurinol sodium for injection is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy. allopurinol sodium for injection is contraindicated in patients with a history of severe reaction to any formulation of allopurinol. based on findings in animals, allopurinol sodium for injection may cause fetal harm when administered to a pregnant woman. adverse developmental outcomes have been described in exposed animals (see data) . allopurinol and its metabolite oxypurinol have been shown to cross the placenta following administration of maternal allopurinol. available limited published data on allopurinol use in pregnant women do not demonstrate a clear pattern or increase in frequency of adverse developmental outcomes. among approximately 50 pregnancies described in published literature, 2 infants with major congenital malf

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - ganciclovir sodium, quantity: 543 mg (equivalent: ganciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - indications as at 12 october 2005: cymevene (ganciclovir) administered as the intravenous infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease. note: cymevene (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage).; imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).;   - powder for infusion - 500mg/500mg - active: cilastatin sodium 571mg equivalent to 500 mg cilastatin acid. (includes 4.6% overage). imipenem monohydrate 560mg equivalent to 500 mg imipenem. (includes 4.6% overage).   excipient: sodium bicarbonate

Singapore - inglese - HSA (Health Sciences Authority)

pharmakoe pte. ltd. - cilastatin sodium eqv cilastatin; imipenem monohydrate eqv imipenem - injection, powder, for solution - cilastatin sodium eqv cilastatin 500mg; imipenem monohydrate eqv imipenem 500mg